McKesson Corporation logo

McKesson Corporation(MCK)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
3-STAR RATING
STRONG BUY
BUY for 89 days
PROFIT SINCE LAST BUY
+35.91% ▲
LAST CLOSE
$1102.81
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for MCK

11/13/2026: MCK (3-star) is a STRONG-BUY. BUY for 89 days. Simulated Profits (35.91%). Updated daily EoD!

McKesson Corporation is a leading healthcare services and wholesale pharmaceutical distribution company operating primarily in North America. The firm benefits from massive supply chain scale, a dominant position in high-margin specialty drug distribution, and robust technology platforms like CoverMyMeds. Its primary growth story centers on expanding specialty care logistics and tech-enabled biopharma services, offset by risks such as thin operating margins, customer concentration, and ongoing regulatory and drug-pricing scrutiny. The stock suits total-return and conservative investors seeking stable exposure to essential healthcare infrastructure, while market participants should monitor specialty segment growth and legislative drug pricing developments.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitWhile earnings growth has been solid due to specialty drug demand, the top-line growth rate reflects a mature wholesale distribution giant.
Momentum investorStrong fit while signal remains positiveMcKesson has frequently exhibited strong medium-term price momentum supported by consistent earnings beats and positive estimate revisions.
Value investorModerate fitThe stock often trades at reasonable price-to-earnings multiples relative to the broader market, though recent outperformance has compressed traditional deep-value appeal.
Dividend investorMixed fitThe company offers reliable dividend growth and consistent buybacks, though its modest dividend yield appeals more to total-return seekers than high-yield income investors.
Low-risk investorStrong fitAs an essential healthcare staple with stable demand profiles and defensive characteristics, it fits conservative portfolios well.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityLowThe stock generally displays lower volatility than high-growth technology sectors due to its defensive business model.
Valuation riskMediumStrong historical outperformance means the stock trades at higher multiples than its historical average, leaving less room for earnings misses.
Competition risk (oligopolistic distributor competition)MediumIntense margin pressure from major peers like Cencora and Cardinal Health limits pricing power in core distribution.
Business qualityStrongMcKesson's deep economic moat as an indispensable healthcare supply chain backbone underpins high franchise quality.
Dividend incomeMediumPayouts are secure and growing, but the low initial dividend yield limits immediate cash income generation.
Execution riskMediumSuccessful execution in scaling specialty distribution and tech solutions is vital to maintaining double-digit EPS growth.

Key Highlights

Company Size Large-Cap Stock
Market Capitalization 127.33B USD
Price to earnings Ratio 28.44
1Y Target Price 1144.29
Price to earnings Ratio 28.44
1Y Target Price 1144.29
Volume (30-day avg) 703.8K shares
Beta 0.28
52 Weeks Range 722.11 - 1121.50
Updated Date 11/15/2026
52 Weeks Range 722.11 - 1121.50
Updated Date 11/15/2026
Dividends yield (FY) 0.32%
Basic EPS (TTM) 38.77

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Medical Distribution

BUY participation
100.0%
Active BUY / eligible
3 / 3
30-Day BUY Count Change
+2

Eligible universe: 3 stocks.

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Strong Uptrend
PRICE PATH

Strong Uptrend

The stock has maintained a strong upward price trend across the last three quarters.

Smooth
PRICE STABILITY

Smooth

The stock has moved along a generally orderly path with only modest fluctuations.

Analysis of Past Performance

Type Stock
Historic Profit 50.31%
Avg. Invested days 51
Today’s Advisory Strong Buy
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 3.0
Stock Returns Performance Upturn Returns Performance icon 3.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
MCK receives a 3-star rating, supported by solid quantitative characteristics, and solid analyst coverage. The rating is constrained by soft unit economics, weak price momentum, and limited analyst upside.

Company Fundamentals

★★★★★
MCK has moderate overall fundamentals (3 stars), with moderate financial health, moderate growth momentum, and solid ownership. In FY2026 versus FY2025, strong earnings growth (+44.5%) and solid revenue growth (+12.4%) are partially offset by soft cash generation (FCF margin 1.3%), soft profitability (net margin 1.2%), very low insider ownership of 0.36%.

Financial Health Rating

★★★★★
MCK's financial health is supported by strong cash strength, including free-cash-flow generation of $5.4B (1.3% of revenue). Profitability is soft (2 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Earnings growth is MCK's strongest growth driver at +44.5% FY2026 versus FY2025 (strong, 5 stars). By comparison, revenue growth (+12.4%, solid) is also solid, while free-cash-flow growth (+3.5%, moderate) holds the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 90.8% and approximately 99.8% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership is only 0.36%, which materially reduces the ownership score.

Top 5 Institutional Investors

BlackRock Inc 9.35%
Vanguard Capital Management, LLC 6.80%
State Street Corp 4.96%
Morgan Stanley - Brokerage Accounts 4.60%
Franklin Templeton Inc 2.52%

Unit Economics (Per $1K Revenue)

★★★★★
MCK generates approximately $36 of gross profit, $16 of operating income, and $13 of free cash flow for every $1,000 of revenue. Based on FY2026 results. Weak margins explain the 2-star rating, with moderate cash conversion and strong capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 17.77%

Quantitative Style Profile

★★★★★
MCK has a large-cap, liquid, relatively low-volatility profile. Weak momentum is the primary drawback, while valuation that is moderately attractive rather than deeply discounted.

Style Classification

Quality Focused

Low VolatilityLarge / Mega Cap StabilityHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
US Pharmaceutical segmentWholesale distribution of brand-name, generic, specialty, and over-the-counter pharmaceutical products.This is the primary revenue engine, generating massive sales volume but operating on very thin percentage margins.
Prescription Technology Solutions (RxTS)Platforms like CoverMyMeds that connect pharmacies, providers, and payers to streamline medication access and affordability.A high-margin technology growth driver that enhances profitability beyond traditional distribution.
Medical-Surgical Solutions segmentDistribution of medical supplies, equipment, and lab products to alternate-site healthcare providers.Provides stable, recurring revenue streams from physician offices and outpatient care centers.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2026-11-04
When After Market
Estimate 10.69
Actual 11.68

Profitability

Profit Margin 1.12%
Operating Margin (TTM) 1.59%

Management Effectiveness

Return on Assets (TTM) 4.72%
Return on Equity (TTM) -

Valuation

Trailing PE 28.44
Forward PE 23.98
Enterprise Value 131.96B
Price to Sales(TTM) 0.3
Enterprise Value 131.96B
Price to Sales(TTM) 0.3
Enterprise Value to Revenue 0.32
Enterprise Value to EBITDA 17.12
Shares Outstanding 115.46M
Shares Floating 115.26M
Shares Outstanding 115.46M
Shares Floating 115.26M
Percent Insiders 0.36
Percent Institutions 90.82

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.